DR BEN SESSA

DR BEN SESSA

DR BEN SESSA

THE PSYCHEDELIC RENAISSANCE: BOLD STEPS ON THE BACK OF AN ELEPHANT.

Whilst the global psychedelic renaissance appears to be in full flow there appear to be some gross challenges from both within and outside the psychedelic community that could impair this march. From outside we remain restricted by strangulating drug prohibition laws that erroneously demonise psychedelics in the eyes of the public. And from within we are faced sometimes by equally dogmatic views and pseudoscientific opinions that threaten to undermine our credibility. Both need to be tackled if we are to truly increase the accessibility of these useful compounds for a doubting general public.

DR BEN SESSA (MBBS BSc MRCPsych) is a consultant child and adolescent psychiatrist working in adult addiction services and with custodial detained young people in a secure adolescent setting. He trained at UCL medical school, graduating in 1997. He is interested in the developmental trajectory from child maltreatment to adult mental health disorders. Dr Sessa is currently a senior research fellow at Bristol, Cardiff and Imperial College London Universities, where he is conducting the UK's first clinical studies with MDMA-assisted therapy for the treatment of PTSD and alcohol dependence syndrome. In the last ten years he has worked on several UK-based human pharmacology trials as study doctor or as a healthy subject administering and receiving test doses of LSD, psilocybin, MDMA and ketamine. He is the author of several dozen peer-reviewed articles in the mainstream medical press and has written two books exploring psychedelic medicine; The Psychedelic Renaissance (2012) and To Fathom Hell or Soar Angelic (2015). In speaking publicly at universities and medical conferences, Dr Sessa is outspoken on lobbying for change in the current system by which drugs are classified in the UK, believing a more progressive policy of regulation would reduce the harms of recreational drug use and provide increased opportunities for clinical psychedelic research. He is a co-founder and director of the UK's Breaking Convention conference.